Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASolute 302: RMC-6236 vs standard chemotherapy in previously treated metastatic PDAC
jRCT2031240614Phase 3Active, not recruiting
- Sponsor
- Revolution Medicines
- Start
- Apr 2025
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of daraxonrasib in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Revolution Medicines. Primary endpoints: Primary efficacy comparison of RMC-6236 vs standard therapy and Safety and tolerability of RMC-6236 in Japanese patients. Started Apr 2025; status: active, not recruiting.
02
Drugs
daraxonrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031240614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240614.